Literature DB >> 25414302

The melanoma revolution: from UV carcinogenesis to a new era in therapeutics.

Jennifer A Lo1, David E Fisher2.   

Abstract

Melanoma, the deadliest form of skin cancer, is an aggressive disease that is rising in incidence. Although melanoma is a historically treatment-resistant malignancy, in recent years unprecedented breakthroughs in targeted therapies and immunotherapies have revolutionized the standard of care for patients with advanced disease. Here, we provide an overview of recent developments in our understanding of melanoma risk factors, genomics, and molecular pathogenesis and how these insights have driven advances in melanoma treatment. In addition, we review benefits and limitations of current therapies and look ahead to continued progress in melanoma prevention and therapy. Remarkable achievements in the field have already produced a paradigm shift in melanoma treatment: Metastatic melanoma, once considered incurable, can now be treated with potentially curative rather than palliative intent.
Copyright © 2014, American Association for the Advancement of Science.

Entities:  

Mesh:

Year:  2014        PMID: 25414302      PMCID: PMC4701046          DOI: 10.1126/science.1253735

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  75 in total

1.  The evolution of current medical and popular attitudes toward ultraviolet light exposure: part 1.

Authors:  Michael R Albert; Kristen G Ostheimer
Journal:  J Am Acad Dermatol       Date:  2002-12       Impact factor: 11.527

2.  Central role of p53 in the suntan response and pathologic hyperpigmentation.

Authors:  Rutao Cui; Hans R Widlund; Erez Feige; Jennifer Y Lin; Dara L Wilensky; Viven E Igras; John D'Orazio; Claire Y Fung; Carl F Schanbacher; Scott R Granter; David E Fisher
Journal:  Cell       Date:  2007-03-09       Impact factor: 41.582

3.  Genome-wide association study identifies three loci associated with melanoma risk.

Authors:  D Timothy Bishop; Florence Demenais; Mark M Iles; Mark Harland; John C Taylor; Eve Corda; Juliette Randerson-Moor; Joanne F Aitken; Marie-Francoise Avril; Esther Azizi; Bert Bakker; Giovanna Bianchi-Scarrà; Brigitte Bressac-de Paillerets; Donato Calista; Lisa A Cannon-Albright; Thomas Chin-A-Woeng; Tadeusz Debniak; Gilli Galore-Haskel; Paola Ghiorzo; Ivo Gut; Johan Hansson; Marko Hocevar; Veronica Höiom; John L Hopper; Christian Ingvar; Peter A Kanetsky; Richard F Kefford; Maria Teresa Landi; Julie Lang; Jan Lubiński; Rona Mackie; Josep Malvehy; Graham J Mann; Nicholas G Martin; Grant W Montgomery; Frans A van Nieuwpoort; Srdjan Novakovic; Håkan Olsson; Susana Puig; Marjan Weiss; Wilbert van Workum; Diana Zelenika; Kevin M Brown; Alisa M Goldstein; Elizabeth M Gillanders; Anne Boland; Pilar Galan; David E Elder; Nelleke A Gruis; Nicholas K Hayward; G Mark Lathrop; Jennifer H Barrett; Julia A Newton Bishop
Journal:  Nat Genet       Date:  2009-07-05       Impact factor: 38.330

Review 4.  Mechanisms of costimulation.

Authors:  Arlene H Sharpe
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

5.  Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.

Authors:  Keiran S M Smalley; Mercedes Lioni; Maurizia Dalla Palma; Min Xiao; Brijal Desai; Suzanne Egyhazi; Johan Hansson; Hong Wu; Alastair J King; Patricia Van Belle; David E Elder; Keith T Flaherty; Meenhard Herlyn; Katherine L Nathanson
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

6.  Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.

Authors:  Mitchell Stark; Nicholas Hayward
Journal:  Cancer Res       Date:  2007-03-15       Impact factor: 12.701

7.  MEK1 mutations confer resistance to MEK and B-RAF inhibition.

Authors:  Caroline M Emery; Krishna G Vijayendran; Marie C Zipser; Allison M Sawyer; Lili Niu; Jessica J Kim; Charles Hatton; Rajiv Chopra; Patrick A Oberholzer; Maria B Karpova; Laura E MacConaill; Jianming Zhang; Nathanael S Gray; William R Sellers; Reinhard Dummer; Levi A Garraway
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-13       Impact factor: 11.205

Review 8.  Genetics of hair and skin color.

Authors:  Jonathan L Rees
Journal:  Annu Rev Genet       Date:  2003       Impact factor: 16.830

9.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

10.  Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi.

Authors:  Catherine D Van Raamsdonk; Vladimir Bezrookove; Gary Green; Jürgen Bauer; Lona Gaugler; Joan M O'Brien; Elizabeth M Simpson; Gregory S Barsh; Boris C Bastian
Journal:  Nature       Date:  2008-12-10       Impact factor: 49.962

View more
  146 in total

1.  The PKC/NF-κB signaling pathway induces APOBEC3B expression in multiple human cancers.

Authors:  Brandon Leonard; Jennifer L McCann; Gabriel J Starrett; Leah Kosyakovsky; Elizabeth M Luengas; Amy M Molan; Michael B Burns; Rebecca M McDougle; Peter J Parker; William L Brown; Reuben S Harris
Journal:  Cancer Res       Date:  2015-09-29       Impact factor: 12.701

2.  Plasma cells in primary melanoma. Prognostic significance and possible role of IgA.

Authors:  Francesca M Bosisio; James S Wilmott; Nathalie Volders; Marjorie Mercier; Jasper Wouters; Marguerite Stas; Willeke Am Blokx; Daniela Massi; John F Thompson; Richard A Scolyer; Nicolas van Baren; Joost J van den Oord
Journal:  Mod Pathol       Date:  2016-02-12       Impact factor: 7.842

3.  Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas.

Authors:  Wanlu Du; Ivan Seah; Oumaima Bougazzoul; GiHun Choi; Katrina Meeth; Marcus W Bosenberg; Hiroaki Wakimoto; David Fisher; Khalid Shah
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-14       Impact factor: 11.205

Review 4.  Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management.

Authors:  Andrzej T Slominski; Anna A Brożyna; Michal A Zmijewski; Wojciech Jóźwicki; Anton M Jetten; Rebecca S Mason; Robert C Tuckey; Craig A Elmets
Journal:  Lab Invest       Date:  2017-02-20       Impact factor: 5.662

5.  From Proteomic Mapping to Invasion-Metastasis-Cascade Systemic Biomarkering and Targeted Drugging of Mutant BRAF-Dependent Human Cutaneous Melanomagenesis.

Authors:  Aikaterini F Giannopoulou; Athanassios D Velentzas; Athanasios K Anagnostopoulos; Adamantia Agalou; Nikos C Papandreou; Stamatia A Katarachia; Dimitra G Koumoundourou; Eumorphia G Konstantakou; Vasiliki I Pantazopoulou; Anastasios Delis; Maria T Michailidi; Dimitrios Valakos; Dimitris Chatzopoulos; Popi Syntichaki; Vassiliki A Iconomidou; Ourania E Tsitsilonis; Issidora S Papassideri; Gerassimos E Voutsinas; Polydefkis Hatzopoulos; Dimitris Thanos; Dimitris Beis; Ema Anastasiadou; George Th Tsangaris; Dimitrios J Stravopodis
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

Review 6.  NRAS mutant melanoma: an overview for the clinician for melanoma management.

Authors:  Russell W Jenkins; Ryan J Sullivan
Journal:  Melanoma Manag       Date:  2016-02-17

7.  Shorter telomere length in Europeans than in Africans due to polygenetic adaptation.

Authors:  Matthew E B Hansen; Steven C Hunt; Rivka C Stone; Kent Horvath; Utz Herbig; Alessia Ranciaro; Jibril Hirbo; William Beggs; Alexander P Reiner; James G Wilson; Masayuki Kimura; Immaculata De Vivo; Maxine M Chen; Jeremy D Kark; Daniel Levy; Thomas Nyambo; Sarah A Tishkoff; Abraham Aviv
Journal:  Hum Mol Genet       Date:  2016-03-02       Impact factor: 6.150

8.  Aberrant SIRT6 expression contributes to melanoma growth: Role of the autophagy paradox and IGF-AKT signaling.

Authors:  Liwen Wang; Weinan Guo; Jinyuan Ma; Wei Dai; Lin Liu; Sen Guo; Jiaxi Chen; Huina Wang; Yuqi Yang; Xiuli Yi; Gang Wang; Tianwen Gao; Guannan Zhu; Chunying Li
Journal:  Autophagy       Date:  2017-12-31       Impact factor: 16.016

9.  A Targeted Quantitative Proteomic Approach Assesses the Reprogramming of Small GTPases during Melanoma Metastasis.

Authors:  Ming Huang; Tianyu F Qi; Lin Li; Gao Zhang; Yinsheng Wang
Journal:  Cancer Res       Date:  2018-08-02       Impact factor: 12.701

10.  Evolutionary selection of personalized melanoma cell/tissue dual-homing peptides for guiding bionanofibers to malignant tumors.

Authors:  Mingying Yang; Yan Li; Yanyan Huai; Chenyuan Wang; Wenfang Yi; Chuanbin Mao
Journal:  Chem Commun (Camb)       Date:  2018-02-08       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.